Please login to the form below

Not currently logged in
Email:
Password:

MYSTIC trial

This page shows the latest MYSTIC trial news and features for those working in and with pharma, biotech and healthcare.

Merck’s Keytruda scores in frontline lung cancer yet again

Merck’s Keytruda scores in frontline lung cancer yet again

That’s not to say Merck’s position in first-line NSCLC is assured - particularly as the data from the latest trial is still under wraps. ... AZ’s combination of Imfinzi (durvalumab) and tremelimumab missed the PFS endpoint in the MYSTIC trial last

Latest news

  • AZ pushes back data read-out from MYSTIC lung cancer trial AZ pushes back data read-out from MYSTIC lung cancer trial

    AZ pushes back data read-out from MYSTIC lung cancer trial. The delay could further undermine confidence in a positive outcome. ... AstraZeneca has delayed reporting the overall survival data from its much-anticipated MYSTIC trial of its immuno-oncology

  • AZ bags key lung cancer approval for Imfinzi AZ bags key lung cancer approval for Imfinzi

    The approval is based on the results of the PACIFIC trial, which showed that patients treated with Imfinzi gained an extra 11 months of progression-free survival (PFS) compared to placebo. ... overall survival data from the MYSTIC trial in first-line

  • Merck chalks up another win for Keytruda in lung cancer Merck chalks up another win for Keytruda in lung cancer

    Meanwhile, Bristol-Myers Squibb - which dropped the ball in first-line NSCLC when Opdivo failed a pivotal trial in 2016 - is waiting on the results of its CHECKMATE-227 of ... 1 blocker Opdivo and CTLA4 inhibitor Yervoy (ipilimumab), and AstraZeneca is

  • AZ CEO says company’s renaissance is on track AZ CEO says company’s renaissance is on track

    The R&D gains offset the “disappointment of the first readout from the MYSTIC trial”of Imfinzi and AZ’s CTLA4 inhibitor tremelimumab in non-small cell lung cancer (NSCLC), he

  • AZ starts pursuit of lung cancer indication for Imfinzi AZ starts pursuit of lung cancer indication for Imfinzi

    has not progressed following platinum-based chemoradiation therapy based on the results of the PACIFIC trial. ... The PACIFIC data upgraded the prospects for Imfinzi after the big disappointment of the MYSTIC trial, in which Imfinzi both alone and paired

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics